ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0841

Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry

Linus Risser1, Torsten Witte2, Peter Bartz-Bazzanella3, Cay Von der Decken4, Johannes Knitza5, Sándor P. Fekete6, Alexander Zink7, Georg Gauler8, Patrick Wurth9, Peer Aries10, Kirsten Karberg11, Christoph Kuhn12, Florian Schuch13, Susanna Späthling-Mestekemper14, Wolfgang Vorbrüggen15, Mathias Englbrecht16, Martin Welcker17 and Stefan Kleinert18, 1Medizinische Hochschule Hannover, Hannover, Germany, 2Hannover Medical School, Hannover, Germany, 3Rhein-Maas Klinikum, Wuerselen, Germany, 4Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, 5Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, University Hospital Erlangen, Erlangen, Germany, 6Department of Computer Science, TU Braunschweig, Braunschweig, Germany, 7Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany, 8rheumapraxis, Osnabrck, Germany, 9Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, 10Rheumatologie in Hamburg, Hamburg, Germany, 11Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, 12Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, 13Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, 14Rheumapraxis München, München, Germany, 15Verein zur Förderung der Rheumatologie e.V., Würselen, Germany, 16Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, 17MVZ für Rheumatologie, Planegg, Germany, 18Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany

Meeting: ACR Convergence 2021

Keywords:

Session Information

Date: Sunday, November 7, 2021

Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) includes achieving remission or at least low disease activity within six months of starting therapy. Active RA may be treated with either biological DMARDs (bDMARDs) or JAK inhibitors after inefficacy or intolerance of conventional DMARDs. To date, only few data are available on the persistence of the different treatment approaches in daily practice.

Methods: Regarding different mode of actions (MoA) for anti-rheumatic treatment, this analysis compares the persistence of JAK inhibitors with TNF inhibitors and other bDMARDs (nonTNFi) in RA patients from the German RheumaDatenRhePort (Rhadar) registry.

Data of 5154 RA patients from the pseudonymized Rhadar registry (Kleinert, S., P. Bartz-Bazzanella et. al. (2021). “A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry.” J Med Internet Res 23(5): e28164.) entered by 22 rheumatologists were evaluated. Patients were included in the sample characterization if at least one registry entry was documented between July 1st, 2020, and March 31st, 2021. Only data of those patients that received a newly prescribed bDMARD or JAK inhibitor between June 1st, 2017 (shortly after the approval of tofacitinib and baricitinib in Germany) and March 31st, 2020, were compared regarding persistence. 3124 (60,6 %) of the evaluated patients suffered from a seropositive RA, 73,5% females, with a mean age of 64.5±13.9 years. 66.9% received monotherapy. The persistence of the respective MoA was calculated using Kaplan-Meier survival curves. Descriptive statistical analysis and drug survival were calculated using R (version 4.0.4) (R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2018) and RStudio (version 1.4.1103) (RStudio Team. RStudio: Integrated Development for R. RStudio, Inc, Boston, MA. 2016).

Results: Prescription information of 4715 of the 5154 patients was available at database closure. Of these 4715 patients, 15.2% received a TNF inhibitor, 8.9% other bDMARDs and 10.0% a JAK inhibitor. JAK inhibitors were prescribed as monotherapy in 64.8%, TNF inhibitors only in 45.4% and other bDMARDs in 63.7% of the RA patients. The persistence on JAK inhibitors, TNF inhibitors and other bDMARDs was high ( > 85% after 24 months) (fig. 1) and did not differ significantly between JAK inhibitors and TNF inhibitors (p = 0.724) or JAK inhibitors and other bDMARDs (p = 0.084) in a corresponding Cox proportional hazards model.

Conclusion: The persistence of therapy with JAK-inhibitors is high in daily practice, comparable to TNF inhibitors and other bDMARDs.

Fig.1: Persistence of the respective therapy principles (MoA = Mode of Action): (JAKi = JAK-inhibitor, TNFi = TNF-inhibitor, IL6i = IL6-receptor-inhibitor, CD20 = Rituximab, CD80/CD86 = Abatacept)

Disclosures: L. Risser, None; T. Witte, AbbVie, 5, Amgen, 5, Bristol-Myers Squibb, 5, Celgene, 5, Chugai, 5, Gilead, 5, Janssen, 5, Eli Lilly, 5, MSD, 5, Mylan, 5, Novartis, 5, Pfizer, 5, Roche, 5, UCB, 5, Merck KGaA, Darmstadt, Germany, 6; P. Bartz-Bazzanella, None; C. Von der Decken, None; J. Knitza, None; S. Fekete, None; A. Zink, None; G. Gauler, Lilly, 1, Abbvie, 1, 6, Gilead, 6, Novartis, 6; P. Wurth, None; P. Aries, None; K. Karberg, None; C. Kuhn, None; F. Schuch, Abbvie, 1, 6, Novartis, 1, 6, Lilly, 1, Gilead, 1, 6; S. Späthling-Mestekemper, None; W. Vorbrüggen, None; M. Englbrecht, None; M. Welcker, Abbvie, 2, 5, 6, Actelion, 5, Aescu, 6, Amgen, 6, Biogen, 6, BMS, 2, 6, Berlin Chemie, 6, Celgene, 2, Galapagos, 2, 5, Gilead, 2, 5, GSK, 2, 5, 6, Hexal, 5, 6, Janssen, 6, Medac, 2, 6, MSD, 6, Mundipharma, 6, Mylan, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, Riemser, 6, Sanofi, 2, 6, UCB, 2, 5, 6; S. Kleinert, Novartis, 5, Abbvie, 1, Siemens Healthineers, 1, Sanofi, 11.

To cite this abstract in AMA style:

Risser L, Witte T, Bartz-Bazzanella P, Von der Decken C, Knitza J, Fekete S, Zink A, Gauler G, Wurth P, Aries P, Karberg K, Kuhn C, Schuch F, Späthling-Mestekemper S, Vorbrüggen W, Englbrecht M, Welcker M, Kleinert S. Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/persistence-on-jak-inhibitors-in-daily-practice-evaluation-of-the-rhadar-registry/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/persistence-on-jak-inhibitors-in-daily-practice-evaluation-of-the-rhadar-registry/